Cutaneous lupus erythematosus

Hansen, Christopher B.; Dahle, Kevin W.

doi:10.1111/j.1529-8019.2012.01508.x

Cited by 11 publications

(7 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment options available to patients with CLE are limited due to toxicities ( Klein et al, 2011 ). Common symptoms experienced by patients with CLE include photosensitivity, itching, burning, and alopecia ( Eastham and Vleugels, 2014 , Hansen and Dahle, 2012 ). These manifestations vary on the degree of severity and persistence depending on the stage and progression of the disease.…”

Section: Introductionmentioning

confidence: 99%

Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study

Ogunsanya

Brown

Lin

et al. 2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

BackgroundCutaneous lupus erythematosus (CLE) is a rare dermatologic autoimmune disease marked by photosensitive lesions that can vary in appearance depending on the subtype. The extent to which CLE affects a patient’s quality of life (QoL) has not been fully characterized. Focus groups were conducted to explore patients’ perspectives of how CLE has affected their lives and to understand the unmet needs in regards to CLE treatment and care.MethodsThis qualitative study involved three focus groups with a total of 19 patients with CLE. A moderator guide containing open-ended questions was used to assess how CLE affects overall QoL. The focus groups were audio-recorded with notetaking. Data were content-analyzed to identify emergent themes.ResultsFour themes emerged as important to patients with CLE: disease sequelae, social interactions, functioning, and unmet needs. Most patients reported decreased QoL due to signs and symptoms such as dyspigmentation and scarring. Having CLE negatively affected patients’ mental health and personal relationships and led to negative coping strategies, such as recreational drug use. Issues related to body image were also elicited by patients. Patients cited unmet needs including lack of treatments to improve chronic skin lesions of CLE and inadequate patient education on living with CLE.ConclusionsProviders can look for signs of QoL impairment in patients with CLE by asking questions related to body image, mental health, social isolation, and coping mechanisms. Future QoL measures can include the effect of CLE-specific attributes such as scarring and dyspigmentation to empower patients’ voices in determining therapeutic efficacy in future clinical trials. Findings from our study have added a new understanding of daily experiences that were elicited directly from patients with CLE.

show abstract

Section: Introductionmentioning

confidence: 99%

Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study

Ogunsanya

Brown

Lin

et al. 2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

show abstract

“…Moreover, systemic corticosteroids were most frequently (in 58.1%) and most successfully (in 96.8%) applied in cases of ACLE, probably due to the frequent association with SLE. The usual oral dose of systemic corticosteroids is 0.5 to 1 mg/kg bodyweight per day for about 2 to 4 weeks followed by tapering of the dose to a minimum (≤7.5 mg/day) with the aim to discontinue the application due to the well‐known side‐effects, such as osteoporosis . Alternatively, a three‐day intravenous (i.v.)…”

Section: Methodsmentioning

confidence: 99%

“…The usual oral dose of systemic corticosteroids is 0.5 to 1 mg/kg bodyweight per day for about 2 to 4 weeks followed by tapering of the dose to a minimum (≤7.5 mg/day) with the aim to discontinue the application due to the well-known side-effects, such as osteoporosis. 31,51,73,74 Alternatively, a three-day intravenous (i.v.) pulse therapy with 1 g methylprednisolone has been successfully used in patients with persistent CLE not responsive to conventional therapy.…”

Section: Systemic Corticosteroidsmentioning

confidence: 99%

S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

Kuhn

Aberer

Bata‐Csörgő

et al. 2016

Acad Dermatol Venereol

147

182

View full text Add to dashboard Cite

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used 'off-label'. The aim of the present guideline was to achieve a broad consensus on treatment strategies for patients with CLE by a European subcommittee, guided by the European Dermatology Forum (EDF) and supported by the European Academy of Dermatology and Venereology (EADV). In total, 16 European participants were included in this project and agreed on all recommendations. Topical corticosteroids remain the mainstay of treatment for localized CLE, and further topical agents, such as calcineurin inhibitors, are listed as alternative first-line or second-line topical therapeutic option. Antimalarials are recommended as first-line and long-term systemic treatment in all CLE patients with severe and/or widespread skin lesions, particularly in patients with a high risk of scarring and/or the development of systemic disease. In addition to antimalarials, systemic corticosteroids are recommended as first-line treatment in highly active and/or severe CLE. Second-and third-line systemic treatments include methotrexate, retinoids, dapsone and mycophenolate mofetil or mycophenolate acid, respectively. Thalidomide should only be used in selected therapy-refractory CLE patients, preferably in addition to antimalarials. Several new therapeutic options, such as B-cell-or interferon a-targeted agents, need to be further evaluated in clinical trials to assess their efficacy and safety in the treatment of patients with CLE. JEADVAll authors are participants of the European Society for Cutaneous Lupus Erythematosus (EUSCLE), which received a grant by the European Academy of Dermatology and Venereology (EADV) to perform the project. This grant was used to organize the consensus conferences and to reimburse the travel fees and the accommodation of each participant. In addition, the grant by the EADV was used to partly reimburse the personnel costs of Aysche Landmann for coordination of the project; and drafting, copy-editing and formatting of the manuscript. Elisabeth Aberer, Zsuszanna Bata-Cs€ org€ o, Marcia Caproni, Andreas Dreher, Camille Frances, Regine Gl€ aser, Hans-Wilhelm Kl€ otgen, Annegret Kuhn, Aysche Landmann, Branka Marinovic, Filippa Nyberg, Rodica Olteanu, Annamari Ranki and Beatrix Volc-Platzer have no conflicts of interest with regard to fees for participation in review activities, such as data monitoring boards, statistical analysis, or end point committees. Jacek C. Szepietowski participated in the Novartis Steering Committee and the Sandoz Data Monitoring Committee. Elisabeth Aberer, Zsuszanna Bata-Cs€ org€ o, Marcia Caproni, Andreas Dreher, Camille Frances, Regine Gl€ aser, Hans-Wilhelm Kl€ otgen, Annegret Kuhn, Branka Marinovic, Filippa Nyberg, Rodica Olteanu, Annamari Ranki, Jacek C. Szepietowski and Beatrix Volc-Platzer have no confl...

show abstract

“…La mejoría de las lesiones de paniculitis mediante el tratamiento con talidomida se ha documentado en varios artículos. En 60 casos de lupus cutáneo resistente al tratamiento, se estudió prospectivamente el efecto de 100 mg diarios de talidomida en el control de la enfermedad 51 . En esta cohorte, cinco pacientes recibieron talidomida para la paniculitis lúpica con mejorías completa o parcial, en un tiempo promedio de seguimiento de nueve meses 52 .…”

Section: Talidomidaunclassified

Paniculitis lúpica

González¹,

Salazar²,

Vela³

et al. 2017

rev. asoc. colomb. dermatol. cir. dematol.

View full text Add to dashboard Cite

La paniculitis lúpica es un subtipo del lupus cutáneo de etiología autoinmunitaria que puede estar relacionada con otras formas de lupus cutáneo, lupus sistémico u otras enfermedades autoinmunitarias. Clínica e histológicamente puede confundirse con el linfoma subcutáneo de células T similar a la paniculitis. El tratamiento de este tipo de paniculitis no se ha estandarizado dada la baja prevalencia de la enfermedad.Se presenta una revisión de los aspectos epidemiológicos, histopatológicos, clínicos y terapéuticos de la paniculitis lúpica.

show abstract

Cutaneous lupus erythematosus

Cited by 11 publications

References 108 publications

Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study

Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study

S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

Paniculitis lúpica

Contact Info

Product

Resources

About